Vivos Therapeutics specializes in diagnostic and treatment methods for patients suffering from dentofacial abnormalities, sleep apnea and snoring.
GM Instruments’ NR6 Rhinomanometer is the only FDA-approved four-phase rhinomanometer used to calculate nasal airway resistance.
The deal provides Vivos with a new revenue stream and a competitive advantage as the sole distributor of the product, chair and CEO Kirk Huntsman said in a June 29 news release.
At the Becker's 5th Annual Future of Dentistry Roundtable, taking place November 12–14 in Chicago, dental leaders and executives will gain insights into emerging technologies, practice growth strategies and the evolving landscape of dental care delivery, with a focus on innovation, patient experience and operational excellence. Apply for complimentary registration now.
